Joseph Michael Taylor Sells 13,095 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 13,095 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00. Following the completion of the transaction, the director directly owned 48,478 shares in the company, valued at $1,134,385.20. This represents a 21.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, June 11th, Joseph Michael Taylor sold 5,500 shares of CeriBell stock. The shares were sold at an average price of $18.41, for a total value of $101,255.00.

CeriBell Stock Up 0.3%

Shares of CeriBell stock opened at $23.33 on Friday. The company has a current ratio of 9.18, a quick ratio of 10.01 and a debt-to-equity ratio of 0.16. The business’s 50 day simple moving average is $18.93 and its 200-day simple moving average is $19.11. The stock has a market capitalization of $895.41 million, a price-to-earnings ratio of -13.26 and a beta of 0.81. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Equities research analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Institutional Trading of CeriBell

Several hedge funds have recently added to or reduced their stakes in CBLL. Royce & Associates LP bought a new position in CeriBell in the 4th quarter valued at about $11,695,000. KCM Capital Inc raised its position in shares of CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after buying an additional 400,000 shares in the last quarter. Kopp Family Office LLC acquired a new stake in shares of CeriBell in the 2nd quarter worth approximately $672,000. Quantinno Capital Management LP boosted its holdings in shares of CeriBell by 3.0% in the first quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock valued at $2,573,000 after acquiring an additional 4,119 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of CeriBell in the first quarter valued at approximately $62,000.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating and set a $28.00 price target on shares of CeriBell in a report on Tuesday, August 11th. Canaccord Genuity Group increased their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.